MedWatch

Bavarian Nordic may start producing covid-19 vaccines next year

If research results and financing pan out, vaccine company Bavarian Nordic reports that a Danish-developed covid-19 vaccine might be ready by next year.

Photo: Bavarian Nordic / PR

If everything comes together, Denmark may have production capacity for a coronavirus vaccine in place as soon as next year. Danish biotech company Bavarian Nordic announced this in relation to Danish Prime Minister Mette Frederiksen's plan that covid-19 vaccines will be produced on Danish soil in 2022.

Bavarian Nordic and scientists from Copenhagen University are currently devleoping a coronavirus vaccine and plan to initiate a phase II trial before the end of June. Bavarian still needs to raise capital for the final phase III trial, but if both the trials and financing efforts are successful, the vaccine might be ready as soon as next year, notes Bavarian Nordic Vice President Investor Relations & Communications Rolf Sass Sørensen.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs